SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 6.8% – What’s Next?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) fell 6.8% on Monday . The stock traded as low as $11.13 and last traded at $11.1880. 3,623,288 shares changed hands during trading, a decline of 56% from the average session volume of 8,305,105 shares. The stock had previously closed at $12.01.

Analyst Ratings Changes

Several analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Friday, July 17th. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, SELLAS Life Sciences Group presently has a consensus rating of “Hold” and an average price target of $10.00.

SELLAS Life Sciences Group Stock Performance

The company has a market capitalization of $2.18 billion, a P/E ratio of -48.24 and a beta of 2.48. The business has a 50 day moving average of $10.92 and a 200-day moving average of $7.15.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Hedge Funds Weigh In On SELLAS Life Sciences Group

A number of large investors have recently modified their holdings of SLS. Larson Financial Group LLC purchased a new stake in SELLAS Life Sciences Group in the 4th quarter worth approximately $26,000. BNP Paribas Financial Markets increased its holdings in shares of SELLAS Life Sciences Group by 89.2% in the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after purchasing an additional 9,299 shares during the period. Concurrent Investment Advisors LLC bought a new position in shares of SELLAS Life Sciences Group in the fourth quarter worth $38,000. Beacon Pointe Advisors LLC purchased a new stake in shares of SELLAS Life Sciences Group in the fourth quarter worth $38,000. Finally, California State Teachers Retirement System raised its position in shares of SELLAS Life Sciences Group by 22.4% in the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after buying an additional 1,709 shares in the last quarter. 17.38% of the stock is currently owned by institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.